Lead Product(s) : Avacc 11
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : CARB-X
Deal Size : $0.6 million
Deal Type : Funding
Intravacc Receives US$ 633K CARB-X Funding for Gonorrhea Vaccine Development
Details : The proceeds will fund Avacc 11, a vaccine against Neisseria gonorrhoeae, using Intravacc’s outer membrane vesicle (OMV) platform technology.
Product Name : Avacc 11
Product Type : Vaccine
Upfront Cash : Undisclosed
January 16, 2024
Lead Product(s) : Avacc 11
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : CARB-X
Deal Size : $0.6 million
Deal Type : Funding
Lead Product(s) : XZ.700
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MEndoC (XZ.700) is a world-class endolysin platform, as a topical treatment of the inflammatory skin symptoms associated with CTCL. Studies have shown that aggressive antibiotic treatment inhibits proliferation of malignant T-cells and disease activity.
Product Name : XZ.700
Product Type : Enzyme
Upfront Cash : Inapplicable
July 03, 2023
Lead Product(s) : XZ.700
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gonorrhea Vaccine Avacc 11
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Avacc 11 (gonorrhea vaccine avacc 11) is the prophylactic intranasal gonorrhea candidate vaccine, consisting of outer membrane vesicles and microsphere encapsulated interleukin-12 induced Th1-driven immunity, with circulating and genital antibodies to Ne...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
January 16, 2023
Lead Product(s) : Gonorrhea Vaccine Avacc 11
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Avacc 101
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : CEPI
Deal Size : $4.8 million
Deal Type : Funding
CEPI Partners With Intravacc To Develop An Intranasal, Broadly Protective Betacoronavirus Vaccine
Details : CEPI’s funding will support preclinical development and testing of Intravacc’s subunit vaccine candidate Avacc 101, which is based on its Outer Membrane Vesicle (OMV) platform.
Product Name : Avacc 101
Product Type : Vaccine
Upfront Cash : Undisclosed
June 10, 2022
Lead Product(s) : Avacc 101
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : CEPI
Deal Size : $4.8 million
Deal Type : Funding
Lead Product(s) : NGoXIM
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : National Institutes of Health
Deal Size : $14.6 million
Deal Type : Funding
Intravacc Awarded US$14.6 Million NIH/NIAID Contract To Develop Intranasal Gonorrhea Vaccine
Details : The grant will support the NG vaccine, called NGoXIM, based on gonococcal OMVs combined with sustained-release microspheres containing recombinant human IL-12, and will be administered intranasally.
Product Name : NGoXIM
Product Type : Vaccine
Upfront Cash : Undisclosed
May 10, 2022
Lead Product(s) : NGoXIM
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : National Institutes of Health
Deal Size : $14.6 million
Deal Type : Funding
Lead Product(s) : Zegocractin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Beijing Zhifei Lvzhu Biopharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Both parties will continue to collaborate to tailor the Avacc 3 concept vaccine for the respective territories, including upscaling, toxicology and clinical trials. Avacc 3 has significant advantages over existing whooping cough vaccines.
Product Name : Avacc 3
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 05, 2022
Lead Product(s) : Zegocractin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Beijing Zhifei Lvzhu Biopharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Nanopharm
Deal Size : Undisclosed
Deal Type : Agreement
Details : Nanopharm will screen and subsequently develop a liquid nasal spray formulation, including performance testing and nasal deposition studies, to prepare Leyden Labs for Phase 1 clinical studies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 21, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Nanopharm
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : ISA104
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Health Holland
Deal Size : Undisclosed
Deal Type : Partnership
ISA Pharmaceuticals, in Partnership with Erasmus MC, is Awarded TKI Grant
Details : ISA104 is an immunotherapy based on ISA's Synthetic Long Peptide (SLP®) technology designed to direct a strong and specific immune response against the hepatitis B virus (HBV), with the aim to cure chronically infected patients.
Product Name : ISA104
Product Type : Vaccine
Upfront Cash : Undisclosed
July 20, 2021
Lead Product(s) : ISA104
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Health Holland
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : ISA106
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ISA106 is an immunotherapy agent that is intended to treat patients with SARS-CoV2 infections, and prevent progressive pneumonia and further complications – thereby avoiding admission to hospital and ICU.
Product Name : ISA106
Product Type : Vaccine
Upfront Cash : Inapplicable
March 03, 2021
Lead Product(s) : ISA106
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rintatolimod
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Aim ImmunoTech
Deal Size : Undisclosed
Deal Type : Agreement
AIM ImmunoTech Enters into Agreement for Proposed Intranasal Safety Study of Ampligen
Details : CHDR, will conduct and manage the proposed clinical study, titled “A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Activity of Repeated Intranasal Administration of Ampligen (Poly I:Poly C12U) in Healthy Subject...
Product Name : Ampligen
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
January 29, 2021
Lead Product(s) : Rintatolimod
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Aim ImmunoTech
Deal Size : Undisclosed
Deal Type : Agreement